US fluid variation study published by Premier

20 November 2015

Deltex Medical Group plc

("Deltex Medical" or "the Company")

US fluid variation 'Big Data' study published by Premier: 650,000 patients in 500 US hospitals

Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), announces the online publication of a Big Data study of variation in fluid management during surgery in the USA, in a leading medical journal.

The study analyses data within the Premier Research Database on circa 650,000 patients in approximately 500 US hospitals undergoing rectal, colonic and hip/knee surgery. The study, supported by Deltex Medical as part of its research collaboration with Premier Inc, has been published online ahead of print in the authoritative Annals of Surgery1.

The key findings from the analysis of the Premier Research Database are highlighted here and are:

In an interview to be included in the Company's forthcoming e-learning module on the Premier findings, one of the academic expert authors of the paper, Professor Mythen, observes:

"I think this is significant in that all of the data collected before is reinforced by this, suggesting that poor fluid management is hurting people and there is plenty of opportunity to do better fluid management. More careful, meticulous attention to detail, combined with, where appropriate, the use of more advanced monitoring has repeatedly demonstrated that patients are more likely to end up in that optimal zone in the middle and have a better outcome."

Premier has published for general access a webinar discussing the key findings at:

www.premierpedia.com/multimedia/premierconnect/21696_Recording-6/Recording/lib/playback.html and is expected to disseminate the paper to its member hospitals once published in print.

1 Thacker J, Mountford W, Ernst F, Krukas M, Mythen M. Perioperative Fluid Utilization Variability and Association With Outcomes: Considerations for Enhanced Recovery Efforts in Sample US Surgical Populations, 2015 Annals of Surgery.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"This is the first 'Big Data' study of the impact of variation in fluid management on patient outcomes and costs. It confirms that reducing such variation should be a high impact focus area for quality improvement in health systems looking to improve patient outcomes, reduce costs or both. This will be highly advantageous to our goal of establishing ODM as a standard of care. We believe ODM is the most precise fluid management technology available, allowing doctors to get patients as close as possible to their individual optimal fluid zone during surgery."

For further information, please contact:-

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

During 2013, the Company launched the CardioQ-ODM+ monitor that offers clinicians both of the two best-established technologies, Deltex Medical's ODM technology as well as Pulse Pressure Waveform Analysis ('PPWA') in one monitor. This allows clinicians to have unique real time insights into each of flow, pressure and resistance, the three pillars of haemodynamics.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and over 600,000 patients have been treated to date using Deltex Medical's single patient disposable probes.